Neurochemical Research

, Volume 33, Issue 2, pp 348–354 | Cite as

Anticonvulsant Efficacy of Drugs with Cholinergic and/or Glutamatergic Antagonism Microinfused into Area Tempestas of Rats Exposed to Soman

Original paper

Abstract

A group of antiparkinson drugs (benactyzine, biperiden, caramiphen, procyclidine, and trihexyphenidyl) has been shown to possess both anticholinergic and antiglutamatergic properties, making these agents very well suited as anticonvulsants against nerve agents. The first purpose of this study was to make a comparative assessment of the anticonvulsant potencies of the antiparkinson agents when microinfused (1 μl) into the seizure controlling area tempestas (AT) of rats 20 min before subcutaneous injection of soman (100 μg/kg). The second purpose was to determine whether cholinergic and/or glutamatergic antagonism was the effective property. The results showed that only procyclidine (6 μg) and caramiphen (10 μg) antagonized soman-induced seizures. Cholinergic, and not glutamatergic, antagonism was likely the active property, since atropine (100 μg), and scopolamine (1 μg) caused anticonvulsant effects, whereas MK-801 (1 μg), and ketamine (50 μg) did not. Soman (11 nmol) injected into AT resulted more frequently in clonic convulsions than full tonic–clonic convulsions. AT may serve as both a trigger site for soman-evoked seizures and a site for screening anticonvulsant potencies of future countermeasures.

Keywords

Antiparkinson drugs Area tempestas Soman Seizures Anticonvulsant effects 

References

  1. 1.
    McDonough JH Jr, Shih T-M (1997) Neuropharmacological mechanisms of nerve agent-induced seizure and neuropathology. Neurosci Biobehav Rev 21:559–579PubMedCrossRefGoogle Scholar
  2. 2.
    Myhrer T, Skymoen LR, Aas P (2003) Pharmacological agents, hippocampal EEG, and anticonvulsant effects on soman-induced seizures in rats. Neurotoxicology 24:357–367PubMedCrossRefGoogle Scholar
  3. 3.
    Myhrer T, Nguyen NHT, Enger S, Aas P (2006) Anticonvulsant effects of GABAA modulators microinfused into area tempestas or substantia nigra in rats exposed to soman. Arch Toxicol 80:502–507PubMedCrossRefGoogle Scholar
  4. 4.
    Myhrer T, Nguyen NHT, Andersen JM, Aas P (2004) Protection against soman-induced seizures: relationship among doses of prophylactics, soman, and adjuncts. Toxicol Appl Pharmacol 196:327–336PubMedCrossRefGoogle Scholar
  5. 5.
    Jouver P, Pain L, Aunis D, Zwiller J (2002) The anesthetics propofol and ketamine inhibit cocain-induced egr-1 gene expression in rat forebrain. Eur J Pharmacol 449:239–243CrossRefGoogle Scholar
  6. 6.
    Sanna E, Mascia MP, Klein RL, Whiting PJ, Biggio G, Harris RA (1995) Actions of the general anesthetic propofol on recombinant human GABAA receptors: influence on receptor subunits. J Pharmacol Exp Ther 274:353–360PubMedGoogle Scholar
  7. 7.
    Gao ZG, Liu BY, Cui WY, Li LJ, Fan QH, Liu CG (1998) Anti-nicotonic properties of anticholinergic antiparkinson drugs. J Pharm Pharmacol 50:1299–1305PubMedGoogle Scholar
  8. 8.
    McDonough JH Jr, Shih T-M (1995) A study of the N-methyl-D-aspartate antagonistic properties of anticholinergic drugs. Pharmacol Biochem Behav 51:249–253PubMedCrossRefGoogle Scholar
  9. 9.
    Raveh L, Weissman BA, Cohen G, Alkalay D, Rabinovitz I, Sonego H, Brandeis R (2002) Caramiphen and scopolamine prevent soman-induced brain damage and cognitive dysfunction. Neurotoxicology 23:7–17PubMedCrossRefGoogle Scholar
  10. 10.
    Gale K (1988) Progression and generalization of seizure discharge: anatomical and neurochemical substrates. Epilepsia 29(Suppl 2):S15–S34PubMedCrossRefGoogle Scholar
  11. 11.
    Löscher W, Ebert U (1996) Basic mechanism of seizure propagation: targets for rational drug design and rational polypharmacy. Epilepsy Res Suppl 11:17–43PubMedGoogle Scholar
  12. 12.
    Ekstrand JJ, Domroese ME, Johnson DMG, Feig SL, Knodel SM, Behan M, Haberly LB (2001) A new subdivision of anterior piriform cortex and associated deep nucleus with novel features of interest for olfaction and epilepsy. J Comp Neurol 434:289–307PubMedCrossRefGoogle Scholar
  13. 13.
    Piredda S, Gale K (1985) A crucial epileptogenic site in the deep prepiriform cortex. Nature 317:623–625PubMedCrossRefGoogle Scholar
  14. 14.
    Myhrer T, Enger S, Aas P (2006) Efficacy of immediate and subsequent therapies against soman-induced seizures and lethality in rats. Basic Clin Pharmacol Toxicol 98:184–191PubMedCrossRefGoogle Scholar
  15. 15.
    Braitman DJ, Sparenborg S (1989) MK-801 protects against seizures induced by the cholinesterase inhibitor soman. Brain Res Bull 23:145–148PubMedCrossRefGoogle Scholar
  16. 16.
    Shih T-M, Koviak TA, Capacio BR (1991) Anticonvulsants for poisoning by the organophosphorous compound soman: pharmacological mechanisms. Neurosci Biobehav Rev 15:349–362PubMedCrossRefGoogle Scholar
  17. 17.
    Schmued LC, Hopkins KJ (2000) Fluoro-Jade B: a high affinity fluorescent marker for the localization of neuronal degeneration. Brain Res 874:123–130PubMedCrossRefGoogle Scholar
  18. 18.
    Capacio BR, Shih T-M (1991) Anticonvulsant actions of anticholinergic drugs in soman poisoning. Epilepsia 32:604–615PubMedCrossRefGoogle Scholar
  19. 19.
    McDonough JH Jr, McLeod CG Jr, Nipwoda T (1987) Direct microinjection of soman or VX into the amygdala produces repetitive limbic convulsions and neuropathology. Brain Res 435:123–137PubMedCrossRefGoogle Scholar
  20. 20.
    Lallement G, Denoyer M, Collet A, Pernot-Marino I, Baubichon D, Monmaur P, Blanchet G (1992) Changes in hippocampal acetylcholine and glutamate extracellular levels during soman-induced seizures; influence of septal cholinoceptive cells. Neurosci Lett 139:104–107PubMedCrossRefGoogle Scholar
  21. 21.
    McDonough JH Jr, Shih T-M (1993) Pharmacological modulation of soman-induced seizures. Neurosci Biobehav Rev 17:203–215PubMedCrossRefGoogle Scholar
  22. 22.
    Shih T-M, McDonough JH Jr, Koplovitz I (1999) Anticonvulsants for soman-induced seizure activity. J Biomed Sci 6:86–96PubMedGoogle Scholar
  23. 23.
    Myhrer T, Andersen JM (2001) Interference with visual memory in rats following infusion of the functional NMDA receptor antagonist, HA-966, into temporal regions. Eur J Pharmacol 428:323–330PubMedCrossRefGoogle Scholar
  24. 24.
    Øydvin OK, Tansø R, Aas P (2005) Pre-junctional effects of oximes on [3H]-acetylcholine release in rat hippocampal slices during soman intoxication. Eur J Pharmacol 516:227–234PubMedCrossRefGoogle Scholar
  25. 25.
    Harris LW, McDonough JH Jr, Stitcher DL, Lennox WJ (1984) Protection against both lethal and behavioral effects of soman. Drug Chem Toxicol 7:605–624PubMedCrossRefGoogle Scholar
  26. 26.
    Kumari M, Ticku MK (2000) Regulation of NMDA receptors by ethanol. Progr Drug Res 54:152–189Google Scholar
  27. 27.
    McDonough JH, Shih T-M, Adams N (1993) Forebrain areas sensitive to the convulsant effects of the anticholinesterase agent VX. Neurosci Abs 19:1630Google Scholar
  28. 28.
    Zimmer LA, Ennis M, Wiley RG, Shipley MT (1998) Nerve gas-induced seizures: role of acetylcholine in the rapid inductions of Fos and glial fibrillary acidic protein in piriform cortex. J Neurosci 15:3897–3908Google Scholar
  29. 29.
    Browning RA, Nelson DK (1986) Modification of electroshock and pentylenetetrazol seizure patterns in rats after precollicular transections. Exp Neurol 93:546–556PubMedCrossRefGoogle Scholar
  30. 30.
    Hudkins RL, Stubbins JF, DeHaven-Hudkins DL (1993) Caramiphen, iodocaramiphen and nitrocaramiphen are potent, competitive, muscarinic M1 receptor-selective agents. Eur J Pharmacol 231:485–488PubMedCrossRefGoogle Scholar
  31. 31.
    Waelbroeck M, Camus J, Tastenoy M, Lambrecht G, Mutschler ETR, Christophe J (1990) Stereoselectivity of procyclidine binding to muscarinic receptor subtypes M1, M2 and M4. Eur J Pharmacol 189:135–142PubMedCrossRefGoogle Scholar
  32. 32.
    Reynolds IJ, Miller RJ (1988) [3H]MK-801 binding to the N-methyl-D-aspartate receptor reveals drug interaction with the zinc and magnesium biding sites. J Pharmacol Exp Ther 247:1025–1031PubMedGoogle Scholar
  33. 33.
    Raveh L, Chapman S, Cohen G, Alkalay D, Gilat E, Rabinovitz I, Weissman BA (1999) The involvement of NMDA receptor complex in the protective effect of anticholinergic drugs against soman poisoning. Neurotoxicology 20:551–560PubMedGoogle Scholar
  34. 34.
    Raveh L, Brandeis R, Gilat E, Cohen G, Alkalay D, Rabinovitz I, Sonego H, Weissman BA (2003) Anticholinergic and antiglutamatergic agents protect against soman-induced brain damage and cognitive dysfunction. Toxicol Sci 75:108–116PubMedCrossRefGoogle Scholar
  35. 35.
    Bajgar J (2004) Organophosphates/nerve agent poisoning: mechanism of action, diagnosis, prophylaxis, and treatment. Adv Clin Chem 38:151–216PubMedCrossRefGoogle Scholar
  36. 36.
    Kassa J, Krejcova G, Samnaliev I (2003) A comparison of neuroprotective efficacy of pharmacological pretreatment and antidotal treatment in soman-poisoned rats. Acta Med (Hradec Kralove) 46:101–107Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  1. 1.Norwegian Defence Research Establishment, Protection DivisionKjellerNorway

Personalised recommendations